Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC By Ogkologos - December 9, 2024 676 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR FDA Approvals Expand Initial Treatment Options for Multiple Myeloma January 7, 2025 How targeted screening can help the NHS save lives from lung... November 23, 2022 Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... January 18, 2022 News digest – ovarian cancer blood test, statins, spending review and... October 31, 2020 Load more HOT NEWS Cancer Research UK’s charity Christmas cards now available Antitumour Activity and Favourable Safety Demonstrated After Treatment with Nivolumab and... “Your Stories” Podcast: Amplifying Patient Voices Trastuzumab Deruxtecan Demonstrates Durable Responses in Patients with Previously Treated HER2-mutated...
